Lombard Odier Asset Management (Switzerland) Sa Biocryst Pharmaceuticals Inc Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $1.45 Million - $2.16 Million	182,839 Added 135.37%	317,901 $2.65 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $1.42 Million - $1.92 Million	135,062 New	135,062 $1.55 Million

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

Vanguard Group Inc Valley Forge, PA

20.3M
Shares

$156 Million
0.0% of portfolio
Black Rock Inc. New York, NY

20M
Shares

$153 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

11.9M
Shares

$91 Million
1.36% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.09M
Shares

$69.7 Million
5.66% of portfolio
State Street Corp Boston, MA

8.85M
Shares

$67.9 Million
0.0% of portfolio

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account